title: Duration of antiinflammatory and symptomatic effects after suspension of intranasal corticosteroid in persistent allergic rhinitis.
abstract: BACKGROUND
  Allergic rhinitis is characterized by an inflammatory response consequent to allergen exposure. Intranasal corticosteroids represent a first line treatment, but there is no adequate knowledge concerning the duration of symptomatic and antiinflammatory effects after their suspension. Thus, we aimed at investigating this issue.
  
  
  METHODS
  Twelve children with persistent allergic rhinitis were treated with FPANS for 30 days and were followed for 12 days after its suspension. Nasal symptoms, considered as TSS, and inflammatory cells, recovered by nasal scraping, were evaluated.
  
  
  RESULTS
  FPANS significantly reduced TSS (p<0.0001), neutrophils (p<0.001), and eosinophils (p<0.0001) after 4 days of treatment. Symptoms and cellular infiltrate quickly reappeared after suspension (respectively after 3 days for symptoms (p<0.05), after 4 days for neutrophils (p<0.05), and 6 days for eosinophils (p<0.001).
  
  
  CONCLUSIONS
  These findings suggest that nasal corticosteroid treatment is highly effective in nasal symptoms' relief and inflammation's control, but its suspension induces a rapid reappearance of them.
authors.affiliation: Allergy, Dpt Head-Neck, San Martino Hospital.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Ciprandi
authors.forename: Vittorio
authors.initials: V
authors.lastname: Ricca
authors.forename: Ferrero
authors.initials: F
authors.lastname: Paola
authors.forename: Bairo
authors.initials: B
authors.lastname: Alessandra
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Riccio
authors.forename: Manlio
authors.initials: M
authors.lastname: Milanese
authors.forename: F
authors.initials: F
authors.lastname: Frati
authors.forename: Maria Angela
authors.initials: MA
authors.lastname: Tosca
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000730:Androstadienes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D004334:Drug Administration Schedule; D004804:Eosinophils / Q000473:pathology; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008925:Mites; D009297:Nasal Mucosa / Q000473:pathology; D009504:Neutrophils / Q000473:pathology; D012008:Recurrence; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D013997:Time Factors
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone